Amgen Buys Roche Privileges To Neutropenia Drugs Amgen said today it really is acquiring Roche’s privileges to the neutropenia medicines filgrastim and pegfilgrastim in approximately 100 markets outside the United States, january 1 effective, 2014, for an undisclosed cost. But since 1989, Roche has held the rights to filgrastim and pegfilgrastim under permit from Kirin-Amgen, a joint venture between Amgen and Japan’s Kirin Holdings, in Eastern Europe, Latin America, Asia, the Middle East, and Africa cognitive function . In those parts of the global world, filgrastim and pegfilgrastim generated a combined approximately $200 million in sales last year. Roche hadn’t disclosed sales for either drug this past year or earlier this season.


The company can be announcing that the pet model studies for the research project to build up both antibodies and vaccines against misfolded SOD1 for the treatment of Alzheimer’s disease have been completed and the results do not support continuing development. September 30 Financial Results The net loss for the 90 days ended, 2010 was $25,728 compared to $1,286,905 for the three months ended September 30, 2009. Related StoriesUnderstanding how schizophrenia impacts workings of the brainFDA grants accelerated acceptance for Tagrisso to take care of patients with advanced NSCLCNew RNA check of blood platelets may be used to detect location of cancerFor the three and six months ended September 30, 2010, revenue from license charges was $1,030,600 in comparison to $nil for the comparable periods.